Pliant Therapeutics grants CMO option on 575K shares

The option's vesting schedule begins September 30, 2027, and conditions vesting on the chief medical officer's continuous service.

Rhea-AI Filing Summary

Pliant Therapeutics (PLRX) awarded Chief Medical Officer David Raben a stock option covering 575,000 shares of common stock on October 1, 2026. The option has a $1.05-per-share exercise price and expires October 1, 2036. Twenty-five percent vests and becomes exercisable on September 30, 2027; the remaining 75% vests in substantially equal monthly installments over three years, subject to his continuous service.

Insider Trade Summary

Grant/Award: 575,000 shares

Grant/Award 1 txn

Insider Raben David

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) F1	575,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 575,000 contracts (Direct)

Footnotes (1)

1. F1. Twenty-five percent (25%) of the shares subject to such option vest and become exercisable on September 30, 2027, and the remaining seventy-five percent (75%) of the shares subject to the option vest and become exercisable in substantially equal installments thereafter on each monthly anniversary of September 30, 2027 (or if there is no corresponding day in any such month, on the last day of each month) over three (3) years, subject to the Reporting Person's continuous service to the Issuer on each such date.

Key Figures

Shares covered by option: 575,000 shares Exercise price: $1.05 per share Initial vesting: 25% +2 more

5 metrics

Shares covered by option 575,000 shares Stock option awarded October 1, 2026

Exercise price $1.05 per share Stock option awarded to David Raben

Initial vesting 25% Vests and becomes exercisable September 30, 2027

Remaining vesting 75% Substantially equal monthly installments over three years

Option expiration October 1, 2036 Stock option awarded to David Raben

Key Terms

Stock Option (Right to Buy), exercise price, vest and become exercisable, continuous service

4 terms

Stock Option (Right to Buy) financial

"Stock Option (Right to Buy)"

exercise price financial

"exercise price"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest and become exercisable financial

"shares subject to such option vest and become exercisable"

continuous service technical

"subject to the Reporting Person's continuous service to the Issuer"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares does David Raben's PLRX stock option cover?

David Raben's option covers 575,000 shares of Pliant Therapeutics common stock and has a $1.05-per-share exercise price. It was awarded on October 1, 2026.

When does David Raben's PLRX stock option expire?

The option expires on October 1, 2036. Twenty-five percent vests and becomes exercisable on September 30, 2027; the remaining 75% vests in substantially equal monthly installments over three years, subject to David Raben's continuous service to Pliant Therapeutics.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/02/2026 - 04:20 PM Accepted by SEC EDGAR 10/02/2026 - 04:20 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Raben David

(Last) (First) (Middle)

C/O PLIANT THERAPEUTICS, INC.

331 OYSTER POINT BOULEVARD

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
PLIANT THERAPEUTICS, INC. [ PLRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.05	10/01/2026		A		575,000		(1)	10/01/2036	Common Stock	575,000	$0	575,000	D

Explanation of Responses:

1. Twenty-five percent (25%) of the shares subject to such option vest and become exercisable on September 30, 2027, and the remaining seventy-five percent (75%) of the shares subject to the option vest and become exercisable in substantially equal installments thereafter on each monthly anniversary of September 30, 2027 (or if there is no corresponding day in any such month, on the last day of each month) over three (3) years, subject to the Reporting Person's continuous service to the Issuer on each such date.

Remarks:

	/s/ Jennifer Woo, attorney-in-fact	10/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)